Drugs / PD-1and ACE2 Knockout T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04990557 | Aug 2021 → Nov 2022 | COVID-19 | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 and ACE2 knockout-T cells | “Programmed cell death protein 1(PDCD1) gene and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 and ACE2 knockout-T cells).” NCT04990557 ↗ |
| Known as | PD-1/ACE2 Knockout T cells | “Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout...” NCT04990557 ↗ |
| Known as | PD-1and ACE2 Knockout Engineered T Cells | “CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients” NCT04990557 ↗ |
| Modality | CRISPR / gene editing | “CRISPR/Cas9-modified Human T Cell” NCT04990557 ↗ |
| Target | ACE2 | “Programmed cell death protein 1(PDCD1) gene and ACE2 gene will be knocked out” NCT04990557 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1(PDCD1) gene and ACE2 gene will be knocked out” NCT04990557 ↗ |